First Tracks said its lead celiac drug nearly prevented gluten-driven villous damage in a challenge study. Its second celiac trial, in more severe patients, reads out in the first quarter of next year.
TRAX · First Tracks Biotherapeutics, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
First Tracks Bio reported AMB033 produced statistically significant celiac gluten-challenge results across histology and patient-reported symptoms, and committed to late-stage celiac trials in 2027. The healing-cohort readout is expected in the first quarter of 2027.
First Tracks said its CD122 antagonist produced best-in-class celiac challenge results, plans four indications and late-stage celiac trials in 2027, and reported over $350 million in cash.
First Tracks Biotherapeutics said ANB033’s Phase 1b celiac Cohort 1 met histologic and symptom endpoints, with placebo-adjusted Vh:Cd improvement of +0.49 (p=0.009) and IEL reduction of -20.03 (p<0.001). Cash and cash equivalents totaled $155.6 million as of September 30, 2026.
First Tracks Biotherapeutics said ANB033 achieved statistically significant protection against gluten-induced intestinal damage and symptoms in a celiac disease Phase 1b cohort. It also completed a $200 million private placement, resulting in $343 million pro forma cash.
First Tracks Biotherapeutics registered 6,106,870 common shares for resale after a private placement at $32.75 per share, closed October 19, 2026, generated approximately $200 million in proceeds. The company will receive no proceeds from the sale.
On October 19, 2026, First Tracks Biotherapeutics, Inc. closed a private placement of 6,106,870 common shares, par value $0.001 per share, and must file or confidentially submit a resale registration statement no later than 30 days after closing.
First Tracks Biotherapeutics, Inc. entered a securities purchase agreement on October 15, 2026, to sell 6,106,870 shares of common stock at $32.75 per share in a private placement, for aggregate gross proceeds of approximately $200 million, expected to close October 19, 2026.
On October 12, 2026, First Tracks Biotherapeutics announced positive Phase 1b Cohort 1 results for ANB033 in celiac disease: a +0.49 placebo-adjusted Vh:Cd ratio delta (p=0.009), a -20.03 IEL density delta (p<0.001), and no safety signals observed to date.